MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Cadazolid

CAS No. : 1025097-10-2

MCE 国际站：Cadazolid

产品活性：Cadazolid (ACT-179811) 是一种新的恶唑烷酮类抗生素，对 Clostridium difficile 具有有效的活性。

研究领域：Anti-infection

作用靶点：Bacterial  |  Antibiotic

In Vitro: Cadazolid is a new antibiotic in development for the treatment of Clostridium difficile-associated diarrhea. Cadazolid is active against all (including linezolid- and moxifloxacin-resistant) Clostridium difficile strains (MIC₉₀ 0.125, range 0.03-0.25 mg/L). The cadazolid geometric mean MIC is 152-fold, 16-fold, 9-fold and 7-fold lower than those of moxifloxacin, linezolid, metronidazole and vancomycin, respectively. Both cadazolid dosing regimens rapidly reduce Clostridium difficile viable counts and cytotoxin with no evidence of recurrence. Cadazolid levels persists at 50-100-fold supra-MIC for 14 days post-dosing. Cadazolid inhibition of enumerated gut microflora is limited, with the exception of bifidobacteria; Bacteroides fragilis group and Lactobacillus spp. counts are unaffected. There is no evidence for selection of strains resistant to cadazolid, quinolones or linezolid.

In Vivo: Cadazolid is well tolerated up to 3000 mg given twice daily for 10 days. The most common adverse event is headache, with no observed relationship between dose or treatment duration and adverse events. Plasma concentrations of cadazolid are low. No plasma concentrations >3.3 ng/mL are observed after single doses or >6.9 ng/mL after 10 days of multiple doses. Food increased the mean Cmax from 0.73 to 1.87 ng/mL and mean AUC0–t from 3.13 to 15.69 ng·h/mL after a single 300 mg dose. The increase in systemic exposure to cadazolid across doses is less than dose-proportional. The mean cumulative faecal recovery is 81.0%–93.5%. Urinary recovery of unchanged compound is less than 0.015%.

相关产品：Natural Product-like Compound Library  |  Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Antibacterial Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  Antibiotics Library  |  Rare Diseases Drug Library  |  Heterocyclic Compound Library  |  Myricetin 3-O-α-L-arabinopyranoside  |  (1R,2S,7R)-Sitafloxacin-d₄ hydrochloride  |  Nebacumab  |  Doxorubicin-¹³C,d₃ TFA  |  Gepotidacin  |  Amycolatopsin A  |  Antibiotic A-33853  |  Estradiol hemihydrate  |  Sulbactam-d₂ sodium  |  Antimicrobial agent-5  |  NBTIs-IN-4  |  Proanthocyanidins  |  Anticancer agent 120  |  Azlocillin sodium salt  |  Antitubercular agent-13  |  Toyocamycin  |  Lenampicillin hydrochloride  |  Hispolon  |  PC58538  |  SPR206 acetate  |  Caracemide  |  Antimicrobial agent-10  |  Doxycycline calcium  |  Antibacterial agent 138  |  Staurosporine  |  Dihydrostreptomycin sulfate  |  Ciclopirox olamine  |  Rubropunctamine  |  Topoisomerase IV inhibitor 2  |  Psoracorylifol C

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。